Psychiatry and Neurology, Neurology · Wilkes Barre, PA
NPI
1043289945
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
1000 E Mountain Blvd
Wilkes Barre, PA, 18711
Phone (570) 820-6028
Groups this clinician bills Medicare through
Medicare paid, 2024
$53K
921 services
Medicare patients, 2024
501
Average age 69
Drug cost, 2024
$2.3M
6,405 prescriptions
Company payments, 2023
$16.95
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mitchell J Gross was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 348 times for 324 patients. In total Mitchell J Gross billed 921 services in 16 codes, and Medicare paid $53K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-08-10.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 348 | 324 | $11.94 | $4,154 |
| 99215 Office E&M - Established | Facility | 236 | 213 | $97.30 | $23K |
| 99214 Office E&M - Established | Facility | 131 | 127 | $62.91 | $8,241 |
| 99204 Office E&M - New | Facility | 75 | 75 | $91.25 | $6,843 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 24 | 23 | $10.91 | $262 |
| 95816 Neurologic | Facility | 19 | 19 | $36.13 | $686 |
| 99214 Office E&M - Established | Office | 18 | 18 | $79.35 | $1,428 |
| 95723 Neurologic | Facility | 16 | 16 | $187.86 | $3,006 |
| 99203 Office E&M - New | Facility | 12 | 12 | $61.65 | $740 |
By year: 2022 $46K for 540 services; 2023 $42K for 534 services; 2024 $53K for 921 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mitchell J Gross prescribed most often to Medicare patients was Gabapentin, with 544 prescriptions and refills. In total Mitchell J Gross wrote 6,405 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 544 | 870 | 134 | $12K |
| Baclofen Generic | 473 | 720 | 115 | $7,261 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 272 | 485 | 66 | $9,123 |
| Clonazepam Generic | 207 | 215 | 28 | $1,912 |
| Pregabalin Generic | 205 | 249 | 39 | $3,314 |
| Lamotrigine Generic | 199 | 388 | 47 | $3,846 |
| Levetiracetam Generic | 194 | 328 | 38 | $6,456 |
| Topiramate Generic | 190 | 428 | 50 | $3,900 |
| Duloxetine Hcl Generic | 180 | 436 | 40 | $3,802 |
| Venlafaxine Hcl Er Venlafaxine Hcl | 146 | 228 | 23 | $1,923 |
| Nortriptyline Hcl Generic | 140 | 284 | 38 | $2,071 |
| Tizanidine Hcl Generic | 134 | 192 | 26 | $2,632 |
| Dalfampridine Er Dalfampridine | 124 | 144 | 15 | $30K |
| Diazepam Generic | 113 | 117 | 16 | $1,180 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 110 | 110 | 14 | $1,780 |
Brand drugs: 409 claims; generic drugs: 5,977 claims; opioid claims: 400.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Mitchell J Gross $16.95 ($16.95 in general payments such as food, travel and fees) from 1 company. The largest payer was EMD Serono, Inc. with $16.95.
| Company | Payments | Amount |
|---|---|---|
| EMD Serono, Inc. MRK.DE | 1 | $16.95 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.